At the 2016 conference in New Orleans, the latest research on SGLT-2 Inhibitors was on display.
The DIC team is just back from the ADA conference, where SGLT-2 Inhibitors research studies were a prominent feature, with over 150 poster presentations on this class alone. We’ll be covering much of this new research in depth over the coming weeks, but for now, here’s a taste of some of the breaking news from the sessions.
Research pertaining to the kidneys was a major topic. In presenting the study Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function, lead researcher Hiddo Lambers Heerspink, Department of Clinical Pharmacy and Pharmacology, University Medical Center, Groningen, noted that the study’s goal was to assess whether canagliflozin slows kidney function decline by comparing the effects of canagliflozin versus glimepiride on eGFR and albuminuria. Researchers concluded that canagliflozin slows the progression of kidney function decline compared to glimepirde at almost equal glycemic control. This suggest that canagliflozin’s beneficial effect on kidney function is independent of its glycemic effects.
Janssen presented results from a Phase 2, randomized study showing glycemic improvements in adults with type 1 diabetes mellitus (T1DM), when treated with canagliflozin (Invokana) plus insulin. Canaglifozen is currently indicated for treatment of type 2, but the new research suggests it has potential in treating type 1 diabetes as well. At the end of the study, canagliflozin 100 mg and 300 mg were associated with a 11.6% and 10.1% increase in the time patients spent within target (glucose >70 to ≤180 mg/dL) and showed comparable reductions in time spent above target (glucose >180 mg/dL) vs. placebo.
Two study results pertaining to AstraZeneca’s Farxiga were presented. In one study, Farxiga was shown to decrease body weight and blood pressure among patients with kidney problems,
In the other study, Farxiga was used in combination with a potassium-sparing diuretic. A1C, body weight and blood pressure were reduced, with no significant increase in potassium levels. This reduces the risk for hyperkalemia.
In other news, the results of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—A Long Term Evaluation (LEADER) trial were major news at the conference on Monday, June 13th. The results showed that liraglutide (Victoza), in patients identified with cardiovascular disease, lowered the combined risk of heart attack, stroke and death from cardiovascular causes by 13%. While a reduction in CV risk with a GLP-1 treatment is an exciting development, there’s not a yet any real evidence of a class effect. Meanwhile, multiple SGLT-2 drugs are undergoing further testing to explore the possibility that SGLT-2 inhibitors as a class can reduce cardiovascular risk.
Stay tuned for more in-depth coverage of key news from the ADA conference.